What recent returns say about Biohaven (BHVN)

Biohaven (BHVN) has had a mixed run recently, with a 2.4% gain over the past day, a 3.3% rise over the past week, a 12.2% decline over the past month, and a 25.1% gain over the past 3 months.

Over longer periods, the stock shows a 9.4% year to date return, a 67.4% decline over the past year, and a 22.4% negative total return over 3 years, giving investors a wide range of outcomes to weigh.

With the latest share price at US$11.86, Biohaven’s recent 3 month share price return of 25.1% contrasts sharply with its 1 year total shareholder return decline of 67.4%. This suggests short term momentum after a tough stretch for longer term holders.

If this kind of rebound in a high risk biotech name has your attention, it can also be a good moment to look across the sector and check out 28 healthcare AI stocks as potential research ideas.

With Biohaven still loss making and the share price well below some analyst targets, the big question is whether the recent rebound leaves room for upside or if the market is already pricing in future growth.

Preferred Multiple of Price to Book: Is it justified?

For Biohaven, the usual shortcut of looking at a price-based multiple does not really work right now. The company has negative shareholders' equity and a P/B ratio of around -91.7x, which is very different to the US biotech industry average of 2.6x.

P/B compares a company's market value to its net assets, so when equity is negative the figure becomes hard to interpret and less useful as a guide for you. In Biohaven's case, liabilities are higher than assets and the business is still loss making, with no meaningful revenue reported and no profitability expected over the next 3 years according to the supplied forecasts.

Because of that balance sheet position, our DCF model also cannot produce a fair value estimate, as there is insufficient data on future cash flows to run a reliable calculation. That leaves investors focusing more on the pipeline, funding mix, and forecast revenue growth of 61.3% a year, rather than any single valuation shortcut.

Result: Preferred multiple of Price to Book (ABOUT RIGHT)

However, you still need to weigh the company’s US$780.11 million net loss and lack of current revenue, as any clinical or funding setback could quickly hit sentiment.

Next Steps

Given the mixed picture so far, do you feel the risks or the potential rewards stand out more? Act while the details are fresh and weigh both sides for yourself, starting with 1 key reward and 5 important warning signs.

Looking for more investment ideas?

Before you move on, take a moment to widen your watchlist with a few focused stock ideas that match different risk and return preferences.

• Target value by reviewing companies our screener flags as 51 high quality undervalued stocks so you are not relying on a single high risk bet.
• Prioritise resilience with a solid balance sheet and fundamentals stocks screener (40 results) and give yourself more confidence about companies’ ability to handle tough conditions.
• Hunt for early opportunities through a screener containing 23 high quality undiscovered gems so you do not miss smaller names that may not be on everyone’s radar yet.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.